Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

An HIV prevention pill that could provide a month of protection per tablet has been given the green light to proceed to pivotal trials to test its efficacy. Spotlight reports on new findings on the ...

Transparent expectation-setting and addressing potential disappointments can foster safety, reduce anxiety, and promote ...

Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a ...

The new drug forces fat cells to produce more energy and doesn't impact appetite or muscle mass, unlike some existing ...

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...

Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical ...